Delivery Order SPE2DB22D9112-SPE2DB25FTKJD
Award Date
1/22/25
Potential Completion Date
2/12/25
Potential Value
$2.1K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $29,587.68 and an ultimate completion date of October 3, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through December 31, 2025. The...
The U.S. Defense Logistics Agency (DLA) awarded a $25,728.84 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of 4,565,176,099 units of the NEXPLANON 68 MG IMPLANTS contraceptive product. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which runs through December 31, 2025. The IDC allows the DLA to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $4,288.14 and a period of performance through March 7, 2024. This delivery order contract is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999, which enables the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of NEXPLANON 68 MG IMPLANTS. The contract, valued at $8,576.28, has an ultimate completion date of July 12, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, that allows the DLA to issue firm fixed-price delivery orders for a...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $3,689.76 and an ultimate completion date of October 17, 2022. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of NEXPLANON 68 MG IMPLANTS. The $42,881.40 contract has an ultimate completion date of October 9, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC allows the DLA...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4,564,185,524 NEXPLANON 68 MG IMPLANTS. The contract has a ceiling value of $3,573.45 and a period of performance through April 24, 2024. This delivery order is part of a larger indefinite delivery contract (SPE2DB22D9112) held by DMS Pharmaceutical Group with the DLA, valued up to $4,999,999, which enables the agency to place...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $2,777.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a wide range of pharmaceutical products, including branded and generic...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Nexplanon 68 mg implants. The contract, valued at $2,858.76, has an ultimate completion date of August 1, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which runs through December 31, 2025. The IDC allows the DLA to issue firm-fixed-price...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of NEXPLANON 68 MG IMPLANTS. The firm fixed-price contract has a ceiling value of $7,146.90 and an ultimate completion date of April 2, 2024. This award is made under DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB22D9207 with DLA, valued up to $4,999,999 through 2025, which enables the agency to issue delivery orders for...